EU Medicines Agency Panel Backs Approval of Kuraci's NovoRapid Biosimilar

MT Newswires · 1d ago
07:07 AM EST, 11/13/2026 (MT Newswires) -- The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Kuraci's Donrafylix, a biosimilar of Novo Nordisk's (NOVO-B.CO) NovoRapid, for diabetes mellitus. The biosimilar insulin aspart, available as a 100 units/milliliter solution for injection, is intended for adults, adolescents and children aged one year and above with the condition, according to a Friday notice.